Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24454
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baecke, C. | - |
dc.contributor.author | GYSSENS, Inge | - |
dc.contributor.author | Decoutere, L. | - |
dc.contributor.author | VAN DER HILST, Jeroen | - |
dc.contributor.author | MESSIAEN, Peter | - |
dc.date.accessioned | 2017-09-13T13:42:32Z | - |
dc.date.available | 2017-09-13T13:42:32Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | NETHERLANDS JOURNAL OF MEDICINE, 75(6), p. 235-240 | - |
dc.identifier.issn | 0300-2977 | - |
dc.identifier.uri | http://hdl.handle.net/1942/24454 | - |
dc.description.abstract | Background: Antiretroviral agents pose a high risk for drug-drug interactions (DDIs), mainly but not limited to being a substrate, inducer or inhibitor of P450 cytochrome enzymes. In part metabolised by other pathways, integrase inhibitors might show a more favourable profile. The aim of this study was to investigate the prevalence of DDIs in daily clinical practice for patients starting different antiretroviral treatment (ART) regimens. Methods: All patients starting ART in our centre from January 2009 to April 2016 were included. All prescribed co-medications since the start of ART were recorded retrospectively from the medical files and screened for DDIs using the Liverpool HIV drug interaction database. Only DDIs between antiretroviral and non-antiretroviral drugs were considered. Results: We included 145 patients, of which 42% were on an integrase inhibitor-based regimen, mainly dolutegravir and elvitegravir. Of the patients, 78% (n = 113) took co-medication. Potential DDIs were seen in 63% of the patients with co-medication; contraindicated prescriptions were detected in 1%. Protease inhibitor-based ART was a risk factor for DDI (odds ratio (OR) 2.57; 95% confidence interval (CI) 1.06-6.19), in contrast to non-nucleoside reverse transcriptase inhibitor-based ART (OR 0.77; 95% CI 0.32-1.84). Concerning integrase inhibitors, a significantly lower risk was seen with dolutegravir-based treatment (OR 0.35; 95% CI 0.15-0.82), though not for elvitegravir-based ART (OR 2.51; 95% CI 0.66-9.58). Conclusions: ART regimens pose a dissimilar risk for drug-drug interactions in clinical practice. Regarding the use of integrase inhibitors, a significantly lower risk was seen with dolutegravir-based treatment. | - |
dc.description.sponsorship | No funding or financial support was received for this work. | - |
dc.language.iso | en | - |
dc.publisher | VAN ZUIDEN COMMUNICATIONS | - |
dc.rights | (C) Van Zuiden Communications B.V. All rights reserved. | - |
dc.subject.other | HIV integrase inhibitors; raltegravir; elvitegravir; dolutegravir; drug-drug interaction | - |
dc.subject.other | HIV integrase inhibitors; raltegravir; elvitegravir; dolutegravir; drug-drug interaction | - |
dc.title | Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 240 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 235 | - |
dc.identifier.volume | 75 | - |
local.format.pages | 6 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Baecke, C.; Gyssens, I. C.; van der Hilst, J. C. H.; Messiaen, P.] Jessa Hosp, Dept Infect Dis & Immun, Hasselt, Belgium. [Gyssens, I. C.; van der Hilst, J. C. H.; Messiaen, P.] Hasselt Univ, BIOMED Res Inst, Hasselt, Belgium. [Gyssens, I. C.] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Nijmegen, Netherlands. [Decoutere, L.] Jessa Hosp, Dept Clin Pharm, Hasselt, Belgium. | - |
local.publisher.place | ALPHEN AAN DE RIJN | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.class | dsPublValOverrule/author_version_not_expected | - |
dc.identifier.isi | 000408099500003 | - |
dc.identifier.url | http://www.njmonline.nl/getpdf.php?id=1869 | - |
item.validation | ecoom 2018 | - |
item.accessRights | Open Access | - |
item.fullcitation | Baecke, C.; GYSSENS, Inge; Decoutere, L.; VAN DER HILST, Jeroen & MESSIAEN, Peter (2017) Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study. In: NETHERLANDS JOURNAL OF MEDICINE, 75(6), p. 235-240. | - |
item.fulltext | With Fulltext | - |
item.contributor | Baecke, C. | - |
item.contributor | GYSSENS, Inge | - |
item.contributor | Decoutere, L. | - |
item.contributor | VAN DER HILST, Jeroen | - |
item.contributor | MESSIAEN, Peter | - |
crisitem.journal.issn | 0300-2977 | - |
crisitem.journal.eissn | 1872-9061 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
getpdf.pdf | Published version | 186.29 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
22
checked on May 17, 2024
Page view(s)
18
checked on Jun 14, 2022
Download(s)
4
checked on Jun 14, 2022
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.